Oncolytics Biotech (TSE:ONC) Shares Pass Above 200 Day Moving Average – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$5.00 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.

Wall Street Analyst Weigh In

Separately, Lake Street Capital raised Oncolytics Biotech to a “strong-buy” rating in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Oncolytics Biotech Stock Performance

The company has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a 50 day moving average price of C$12.50 and a 200-day moving average price of C$5.00. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.